Biden's Push to Expand Anti-Obesity Drug Coverage for Medicare & Medicaid

President Joe Biden proposes expanding Medicare and Medicaid coverage for anti-obesity drugs, potentially reducing costs by up to 95%. This could broaden access to life-saving medications for millions, addressing obesity-related health risks. The initiative aligns with Biden's ongoing efforts to lower healthcare costs, amidst pending legal challenges.

President Joe Biden is set to propose a significant expansion in Medicare and Medicaid's coverage for anti-obesity drugs, offering potential out-of-pocket savings of up to 95%, according to a White House official.

The proposed overhaul aims to make weight loss medications, which mitigate serious health risks like type 2 diabetes and heart attacks, more affordable and accessible. Traditionally, these drugs have not been covered for obesity as a standalone condition, despite costing up to $1,000 monthly without insurance.

This initiative aligns with Biden's broader healthcare cost-reduction goals, which also include capping Medicare insulin costs and negotiating drug prices. However, the plan faces legal scrutiny as industry groups contest its constitutionality, reflecting ongoing challenges in U.S. healthcare reform.

(With inputs from agencies.)